Skip to main content
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc. — Investor Relations & Filings

Ticker · VERA ISIN · US92337R1014 US Professional, scientific and technical activities
Open in API
Filings indexed 418 across all filing types
Latest filing 2022-06-13 Capital/Financing Update
Country US United States of America
Listing US VERA

About Vera Therapeutics, Inc.

https://veratx.com/

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological and rare diseases. The company's mission is to change the standard of care and improve patients' lives. Its lead product candidate is atacicept, a novel biologic molecule being developed for the treatment of IgA nephropathy (IgAN), a progressive autoimmune kidney disease. Vera Therapeutics aims to advance its pipeline of innovative therapies to address significant unmet medical needs within immunology.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(5) under the Securities Act, describing a shelf registration for up to $400 million of various securities including common stock, preferred stock, debt securities, and warrants. It provides general information about the securities, the company, risk factors, and legal matters. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to capital raising but is not an update on financing activities or capital structure changes per se. The document is a formal registration prospectus used to offer securities to investors, which fits the category of Capital/Financing Update (CAP). The length and detail confirm it is the actual prospectus, not just an announcement. Therefore, the best classification is CAP.
2022-06-13 English
Regulatory Filings 2022
Regulatory Filings
2022-06-09 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from Vera Therapeutics, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a correspondence related to a securities registration process, specifically a request under Rule 461 of the Securities Act. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to capital raising but is not itself a capital/financing update or a report. Given the short length (1723 characters) and the nature of the content (a formal request letter to the SEC), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2022-06-09 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering. It includes a base prospectus and a sales agreement prospectus for offering up to $400 million of various securities including common stock, preferred stock, debt securities, and warrants. The document is a regulatory filing related to capital raising activities and securities registration, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement document. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-06-03 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-02 English
FORM 4 SUBMISSION
Director's Dealing
2022-05-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.